Intuitive Surgical, Inc. (ISRG) reported $2.44 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 21.4%. EPS of $2.19 for the same period compares to $1.78 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.35 billion, representing a surprise of +3.93%. The company delivered an EPS surprise of +14.06%, with the consensus EPS estimate being $1.92.While investors scrutinize revenue and earnings changes year-over-year and how they compare w ...

Key Takeaways ISRG is projected to report Q2 revenue of $2.35B and EPS of $1.92, with 15-17% procedure growth in 2025. Strong da Vinci 5 placements and Ion adoption likely drove ISRG's Q2, but bariatric weakness may offset gains. Tariff risks, elevated valuation, and global CapEx strain could limit ISRG upside despite solid fundamentals.Intuitive Surgical, Inc. (ISRG) is set to report second-quarter 2025 earnings on April 22. The Zacks Consensus Estimate for sales and earnings is pegged at $2.35 billion a ...

Core Viewpoint - The article suggests that three industry leaders with strong catalysts and competitive advantages could outperform current AI leaders Nvidia and Palantir over the next decade. Group 1: Nvidia and Palantir - Nvidia has gained over $3.8 trillion in market value since the start of 2023, while Palantir's stock has surged approximately 2,250% during the same period [2] - Nvidia's GPUs, particularly the Hopper and Blackwell models, dominate AI-accelerated data centers, allowing the company to charge a significant premium due to ongoing AI-GPU scarcity [4] - Palantir's platforms, Gotham and Foundry, are essential for federal governments and businesses, driving sales growth and recurring profitability [5] - Both companies may be in a bubble, as historical trends suggest that major innovations often experience bubble-bursting events [6] - Palantir's price-to-sales (P/S) ratio is nearing 121, while Nvidia's is approaching 29, significantly higher than peers [7] Group 2: Potential Competitors - Alibaba Group, with a current market cap of $276 billion, is positioned to potentially surpass Nvidia and Palantir, benefiting from its e-commerce dominance and cloud infrastructure services [10][11] - Alibaba's Taobao and Tmall platforms accounted for an estimated 41% of China's online retail market in 2024, supported by a growing middle class [11] - Alibaba Cloud captured one-third of all cloud infrastructure spending in mainland China, with generative AI solutions expected to drive double-digit sales growth [12] - PayPal Holdings, with a market cap of $71 billion, is also a strong contender, as the global fintech market is projected to grow significantly [14][15] - PayPal's total payment volume increased from $936 billion to an annual run rate of $1.67 trillion, indicating strong engagement from active accounts [16] - Intuitive Surgical, valued at $184 billion, has a stronghold in the robotic-assisted surgical market, with a growing revenue stream from high-margin instruments and services [19][21][22] - The company is expanding its surgical systems' applications, which could sustain double-digit growth for the next decade [23]

Key Takeaways ISRG received FDA clearance for its Vessel Sealer Curved, expanding its da Vinci surgical instrument lineup. ISRG's new tool performs four functions in one, improving control and efficiency in tight anatomical spaces. ISRG enhanced the design with better visibility and versatility, plus clearance to transect lymphatic vessels.Intuitive Surgical (ISRG) recently received FDA clearance for its Vessel Sealer Curved, a multifunctional instrument designed for use with compatible da Vinci surgical ...

In its upcoming report, Intuitive Surgical, Inc. (ISRG) is predicted by Wall Street analysts to post quarterly earnings of $1.92 per share, reflecting an increase of 7.9% compared to the same period last year. Revenues are forecasted to be $2.35 billion, representing a year-over-year increase of 16.8%.The consensus EPS estimate for the quarter has undergone an upward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed ...

Core Viewpoint - Intuitive has successfully demonstrated its telesurgery capabilities by connecting two surgeons remotely to perform a transatlantic surgery at the Society of Robotic Surgery conference, showcasing advancements in robotic-assisted surgery technology [1][2][4]. Company Overview - Intuitive, headquartered in Sunnyvale, California, is a leader in minimally invasive care and robotic surgery, with a focus on improving patient outcomes and care delivery efficiency [11]. - The company has developed the da Vinci surgical system, which has been used in nearly 17 million procedures over 30 years, training almost 90,000 surgeons [8]. Telesurgery Demonstration - The demonstration involved Dr. Doug Stoddard in Georgia and Dr. Andrea Pakula in France, using a dual console da Vinci 5 system to perform surgery on an advanced tissue model [2][3]. - The surgeons were able to exchange control of surgical instruments remotely, utilizing Force Feedback technology to simulate the sensation of operating on live tissue despite being over 4,000 miles apart [3]. Future of Telesurgery - Intuitive's CEO emphasized the potential of telesurgery to enhance patient access to care, while also noting the importance of careful development in infrastructure and technology to ensure safety and reliability [4][6]. - The company is focused on building a robust network infrastructure to support telesurgery, rather than being the first to market [7]. Technology Development - The telesurgery software demonstrated is still in development and not yet cleared for sale or use in the U.S. or EU, indicating ongoing efforts to ensure safety and effectiveness [9]. - Intuitive's telecollaboration suite includes telementoring and teleproctoring, aimed at improving clinical outcomes and reducing care costs [6].

Core Insights - Intuitive has received FDA clearance for its latest advanced energy instrument, the Vessel Sealer Curved, designed for use with its multiport da Vinci systems [1][2] - The Vessel Sealer Curved is the first of Intuitive's advanced energy instruments cleared for the transection of lymphatic vessels, enhancing its multifunctionality and precision [2][4] Product Features - The Vessel Sealer Curved features a slim, curved jaw that follows anatomical contours, improving visibility and control in tight spaces [3] - It is designed for grasping, blunt dissection of tissue, bipolar coagulation, and mechanical transection of blood vessels up to 7mm in diameter, as well as lymphatic vessels [4] Company Background - 2025 marks the 30th anniversary of Intuitive in developing robotic-assisted technology, with nearly 17 million da Vinci procedures performed and around 90,000 surgeons trained [5] - Intuitive aims to improve patient outcomes, enhance care team experiences, increase access to minimally invasive care, and reduce treatment costs [5][6] Technology Overview - The da Vinci surgical systems provide high-definition 3D vision and robotic assistance, enabling precise dissection and reconstruction during minimally invasive surgeries [7]

Core Insights - The rapid rise of Palantir Technologies in the AI sector may be temporary, with concerns about its high valuation and market sustainability [5][8][7] AI Market Overview - The global addressable market for AI is projected to reach $15.7 trillion by 2030, indicating significant growth potential for various companies [2] Palantir Technologies - Palantir's stock has surged by 1,940% since the beginning of 2023, leading to a market cap exceeding $300 billion [5] - The company has a sustainable competitive advantage with its Gotham and Foundry platforms, which are difficult for competitors to replicate [6] - Palantir's business model includes multiyear government contracts and an enterprise-based subscription model, contributing to predictable cash flow [6] - Despite its strengths, Palantir faces historical challenges that have affected other tech companies, including potential overvaluation and negative investor sentiment [7] - Palantir's price-to-sales (P/S) ratio is currently above 104, significantly higher than the historical range of 30 to 43 for leading companies in similar trends, suggesting an unsustainable valuation [8] Competitors with Growth Potential - Pfizer, with a current market cap of $142 billion, is positioned to grow stronger, especially with its oncology segment bolstered by the acquisition of Seagen [10][13] - PayPal, valued at $73 billion, offers a more attractive risk-reward profile with sustained double-digit growth potential and a forward price-to-earnings ratio of 13 [16][20] - Intuitive Surgical, with a market cap of $193 billion, dominates the robotic-assisted surgical market and is expected to see revenue growth driven by higher-margin services and accessories [21][25]

Core Insights - Intuitive Surgical has received CE mark approval for its da Vinci 5 Surgical System for both adult and pediatric use in Europe, enabling minimally invasive endoscopic procedures [1][3] - The da Vinci 5 is the most advanced multiport robotic-assisted surgical system, featuring over 150 enhancements and building on the design of the da Vinci Xi Surgical System [2][4] - The da Vinci surgical systems have been utilized in over 410,000 procedures in Europe in 2024 and nearly 17 million procedures globally to date [2][7] Company Developments - The da Vinci 5 Surgical System is designed to improve surgical outcomes, efficiency, and provide actionable insights for healthcare systems [4][8] - Intuitive has been developing robotic-assisted technology for 30 years, with nearly 90,000 surgeons trained worldwide [7] - The da Vinci 5 system offers enhanced surgical capabilities, including advanced 3D vision, ergonomic design, and operational efficiencies [8][10] Market Impact - The introduction of the da Vinci 5 provides surgeons in Europe with greater choice and flexibility, supporting quality care for more patients [5][6] - The system aims to address critical challenges faced by healthcare systems across Europe, potentially transforming surgical practices [4][5]

Core Insights - The da Vinci 5 Surgical System has received CE mark approval for use in Europe, allowing for minimally invasive endoscopic procedures in both adult and pediatric patients [1][3] - This system is the most advanced in the da Vinci series, featuring over 150 enhancements and has been utilized in more than 410,000 procedures in Europe in 2024 and nearly 17 million procedures globally [2][7] Company Overview - Intuitive is a leader in minimally invasive care and robotic-assisted surgery, celebrating its 30th year of developing such technologies [7][9] - The company aims to improve patient outcomes, enhance the experience for patients and care teams, increase access to minimally invasive care, and reduce treatment costs [7][9] Product Features - The da Vinci 5 system includes advanced features such as Force Feedback technology, a high-definition 3D vision system, and an ergonomic surgeon console [8] - It offers operational efficiencies through greater surgeon autonomy and a streamlined workflow, making it easier for care teams to use [8] - The system is powered by an intelligent platform with significantly enhanced computing capabilities, providing actionable insights for surgical performance improvement [8] Market Impact - The introduction of the da Vinci 5 system is expected to transform surgical practices and address challenges faced by healthcare systems in Europe [4][5] - Surgeons and care teams will have access to a full portfolio of da Vinci systems, enhancing choice and flexibility in surgical options [5][6]